PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

| Complete if Known | | | | | |
|------------------------|-------------------|--|--|--|--|
| Application Number | 10/810,165 | | | | |
| Filing Date | 03/26/2004 | | | | |
| First Named Inventor | David S. F. Young | | | | |
| Art Unit | 1642 | | | | |
| Examiner Name | | | | | |
| Attorney Docket Number | 2056.040 | | | | |

U. S. PATENT DOCUMENTS Name of Patentee or Pages Columns Lines Where Examiner **Document Number** Publication Date MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Figures Appear Number-Kind Code^{2 (d known)} US- 4.861,581 LAR 08/29/1989 Epstein et al US- 5,171,665 12/15/1992 Hellstrom et al US- 5,484,596 01/16/1996 Hanna, Jr., et al . 12/02/1997 Codington et al US-5,693,763 ^{US-} 5,750,102 05/12/1998 Eisenbach et al US- 5,780,033 07/14/1998 Torchilin et al US- 5,783,186 07/21/1998 Arakawa et al US- 5,849,876 12/15/1998 Linsley et al US- 5.869.045 Hellstrom et al 02/09/1999 US- 5,869,268 02/09/1999 Kudo et al ^{US-} 5,916,561 Adolf et al 06/29/1999 ^{US-} 5,616,468 Salmi et al 04/01/1997 US- 5,879,898 03/09/1999 Tarin et al US-5,942,417 08/24/1999 Ni et al US- 5,885,575 03/23/1999 Herrlich et al US- 6,180,357 01/30/2001 Young et al US- 6,657,048 Young et al 12/02/2003 US- 2003/0103985 06/05/2003 Adolf et al US- 2004/0105815 06/03/2004 Young et al

| ſ | | FORE | IGN PATENT DOCU | JMENTS | | |
|-----------------------|--------------|---|---------------------|--|---|-----|
| Examiner Initials* | Cite No.1 | Foreign Patent Document | Publication Date | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages | |
| | | Country Code ³ Number ⁴ Kind Code ⁵ (if known) | MM-DD-YYYY | | Or Relevant Figures Appear | Τ° |
| LAB | | WO02/094879 | 11/28/2002 | Boehringer Ingelheim Int'i GMBH et al | | |
| | | | | | <u>.</u> | |
| | <u> </u> | | | <u></u> | | Ļ., |
| | | | | | ļ | ╁ |
| <u> </u> | - | | | ļ | | - |
| | | | | | | |

Examiner Signature Date Considered 4/19/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copylof this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

2056.040

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO Application Number 10/810,165 Filing Date 03/26/2004 INFORMATION DISCLOSURE First Named Inventor David S. F. Young STATEMENT BY APPLICANT Art Unit 1642 (Use as many sheets as necessary) **Examiner Name**

Attorney Docket Number

| | | | | DOCUMENTS | |
|-----------------------|--------------|---|--------------------------------|--|--|
| Examiner Initials* | Cite No.1 | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant |
| | | Number-Kind Code ^{2 (d known)} | | | pplicant of Cited Document Relevant Passages or Relevant Figures Appear |
| 100 | | ^{US-} 2005/0008646 | 01/13/2005 | Young et al | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | L | US- | - | | |

| | | FOREI | GN PATENT DOCU | IMENTS | | |
|--------------------|--------------|---|-----------------------|--|---|----|
| Examiner Initials* | Cite No.1 | Foreign Patent Document | Publication Date | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages | |
| | | Country Code ³ Number ⁴ Kind Code ⁵ (if known) | MM-DD-YYYY | | Or Relevant Figures Appear | ۲° |
| | | | | | | _ |
| | <u> </u> | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| Examiner Signature | FS consulter | ar Th | Date Considered | 4/10/10/ |
|-----------------------|--------------|----------|--------------------|----------|
| | S Carrer | <u> </u> | Considered | 7/19/06 |
| | | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not inconformance and not considered. Include copy of his form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patient Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the eyear of the reign of the Empirer must precede the serial number of the patent document. Mind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it contains a valid OMB control number.

| Under the Paperwork Reduction Act of 1995, no persons are | U.S. Patent a required to respond to a collection of | of information unless it contains a valid OMB control number. Complete if Known |
|---|--|--|
| Substitute for form 1449/PTO | Application Number | 10/810,165 |
| | Filing Date | 03/26/2004 |
| INFORMATION DISCLOSURE | First Named Inventor | David S. F. Young |
| STATEMENT BY APPLICANT | Art Unit | 1642 |
| (Use as many sheets as necessary) | Examiner Name | |
| 6 | Attorney Docket Number | 2056.040 |
| Sheet 3 of 6 | | : |

| | | NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of linclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of linclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of linclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of linclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of linclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of linclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of linclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of linclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of linclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of linclude name of the author (in CAPITAL LETTERS), title of linclude name of the article (when appropriate), title of linclude name of the article (when appropriate), title of linclude name of the article (when appropriate), title of linclude name of the article (when appropriate), title of linclude name of the article (when appropriate), title of linclude name of the article (when appropriate), title of linclude name of the article (when appropriate), title of linclude name of the article (when appropriate), title of linclude name of the article (when appropriate), title of linclude name of the article (when appropriate), title of linclude name of the article (when appropriate), title of linclude name of the article (when appropriate), title of linclude name of the article (when appropriate), title of linclude name of the article (when appropriate), title of linclude name of the article (when appropriate), title of linclude name of the article (when appropriate), title of linclude name of the articl | T ² |
|--------------------|--------------|--|----------------|
| kaminer itials* | Cite No.1 | The item (book maddatile, journal and the country where bunished. | |
| 1 100 | | number(s), publisher, city and/or county three produced apoptosis in human M. ALLOUCHE et al, "Ligation of the CD44 adhesion molecule inhibits drug-induced apoptosis in human myeloid leukemia cells", Blood, 96(3):1187-1190 (August, 2000) | |
| 48 | ļ | BARSHACK et al, CD44 expression in normal adrenal tissue and adrenal tumors", J. Clin. Pathol., 51:52-54 | |
| | | 1/4000\ | |
| | - | R. BREYER et al, "Disruption of intracerebral progression of C6 rat glioblastoma by in vivo treatment with anti- CD44 monoclonal antibody", J. Neurosurg., 92:140-149 (January, 2000) | |
| | - | COLNOT et al. "Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood | |
| | | dose escalation study, daily compared to particular and neck squamous cells carcinoma:initial | |
| | | evnerience", Head & Near, 2010 | |
| | +- | D. COLNOT et al, "Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck", J. Nucl. Med., 41:1999-2010 (December, 2000) | |
| | | D. COLNOT et al, "Evaluation of limited blood sampling in a preceding 99mTC-labeled diagnostic study to D. COLNOT et al, "Evaluation of limited blood sampling in a preceding 99mTC-labeled diagnostic study to D. COLNOT et al, "Evaluation of limited blood sampling in a preceding 99mTC-labeled diagnostic study to D. COLNOT et al, "Evaluation of limited blood sampling in a preceding 99mTC-labeled diagnostic study to D. COLNOT et al, "Evaluation of limited blood sampling in a preceding 99mTC-labeled diagnostic study to D. COLNOT et al, "Evaluation of limited blood sampling in a preceding 99mTC-labeled diagnostic study to D. COLNOT et al, "Evaluation of limited blood sampling in a preceding 99mTC-labeled diagnostic study to D. COLNOT et al, "Evaluation of limited blood sampling in a preceding 99mTC-labeled diagnostic study to D. COLNOT et al, "Evaluation of limited blood sampling in a preceding 99mTC-labeled diagnostic study to D. COLNOT et al, "Evaluation of limited blood sampling in a preceding 99mTC-labeled diagnostic study to D. Colnot et al, "Evaluation of limited blood sampling in a preceding 99mTC-labeled diagnostic study to D. Colnot et al, "Evaluation of limited blood sampling in a preceding 99mTC-labeled diagnostic study to D. Colnot et al, "Evaluation of limited blood sampling in a preceding sampling sampling in a preceding sampling sampling sampling in a preceding sampling sampling sampling sampling sampling sampling | |
| | | (9):1364-1367 (September, 2001) A. DAAR et al, "The membrane antigens of human colorectal cancer cells:demonstration with monodonal antibodies of heterogeneity within and between tumours and of anomalous expression of HLA-DR*, Eur. J. antibodies of heterogeneity 2009-220 (1983) | |
| | | Cancer Clin. Oncol., 19(2):209-220 (1983) | |
| | | head and neck cancer passents ? | - |
| 1 | | R. DE BREE et al, "Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer", Clin. Can. Res., 1:591-598 (June, 1995) | |

| V | | | , |
|-------------|---|--------------------------------|--------------------------------------|
| | | Date | 11/1alAL. |
| Λ | ~ `\() | Considered | 7/11/00 |
| Examiner | man of Media | Draw line through C | tation if not in conformance and not |
| Signature 0 | An existered whether or not citation is in conformance with | h MPEP 609. DISW line times 5. | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of his form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO This collection of Information is required by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete on the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the USPTO. Time will vary depending upon the individual case. Any comments on the USPTO. The will vary depending upon the individual case. Any comments on the USPTO. Time will vary depending upon the individual case. Any comments on the USPTO. Time will vary depending upon the individual case. Any comments on the USPTO. Time will vary depending upon the individual case. Any comments on the USPTO. Time will vary depending upon the individual case. Any comments of the USPTO. Time will vary depending upon the individual case. Any comments of the USPTO. Time will vary depending upon the i Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/S8/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
of collection of information unless it contains a valid OMB control number.

| | Under the Paperwork Reduction Act of 1995, no persons are | U.S. Patent a required to respond to a collection of | of information unless it contains a valid OMB control number. Complete if Known |
|---|---|--|--|
| 4 | Substitute for form 1449/PTO | Application Number | 10/810,165 |
| ۱ | | | 03/26/2004 |
| ١ | INFORMATION DISCLOSURE STATEMENT BY APPLICANT | First Named Inventor | David S. F. Young |
| | STATEMENT BY ALL LIST | Art Unit | 1642 |
| | (Use as many sheets as necessary) | Examiner Name | |
| | | Attorney Docket Number | 2056.040 |
| | Sheet 4 of 6 | | |

| xaminer | Cite | NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when approp the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), value the item (book, magazine, publisher, city and/or country where published. | riate), title of rolume-issue | T ² |
|---------|------|--|-------------------------------|----------------|
| itials* | No.1 | the item (book, magazine, journal, serial, symposium, catalog, etc.), the item (book, magazine, journal, serial, symposium, catalog, etc.), number(s), publisher, city and/or country where published. S. DENNING et al, "Antibodies against the CD44 p80, lymphocyte homing receptor molecule au peripheral blood T cell activation", J. Immunol., 144:7-15 (January, 1990) | gment human | |
| LB | | B. FLANAGAN et al, "Chemical composition and tissue distribution of the human CDw44 glycop | orotein*, | |
| _ | | S. FOX et al, "Normal human tissues, in addition to some tumors, express multiple different CD Cancer Res., 54:4539-4546 (August, 1994) | | |
| _ | - | U. GUNTHERT et al, "A new variant of glycoprotein CD44 confers metastatic potential to rat ca Cell, 65:13-24 (April, 1991) | | |
| | +- | Y. GUO et al, "Inhibition of human melanoma growth and metastasis in vivo by anti-CD44 mor Cancer Res., 54:1561-1565 (March, 1994) | | |
| | - | K. HEIDER et al, "Differential expression of CD44 splice variants in intestinal- and diffuse-type carcinomas and normal gastric mucosa", Cancer Res., 53:4197-4203 (September, 1993) | | |
| | | K. HEIDER et al, "A human homologue of the rat metastasis-associated variant of CD44 is et colorectal carcinomas and adenomatous polyps", J. Cell Biol., 120:27-233 (January, 1993) | | |
| | + | K. HEIDER et al, "Splice variants of the cell surface glycoprotein CD44 associated with meta are expressed in normal tissues of humans and cynomolgus monkeys", Eur. J. Cancer, 31A (1995) | | |
| | | K. HEIDER et al., "Characterization of a high-affinity monoclonal antibody specific to Co445 immunotherapy of squamous cell carcinomas", Cancer Immunol. Immunother., 43:245-253 | | - |
| - | - | S. JALKANEN et al, "Biochemical properties of glycoproteins involved in lymphocyte recogned by the state of t | אנים מים חוקרו | |

| 1 1/2 1 | | | |
|------------|---|----------------------------|---------------------------------------|
| | A | Date | 11/10/1/ |
| Funminer 1 | T 3 (4) | Considered | 7/17/06 |
| Examiner | Summer Superher or not citation is in conformar | MED 609 Drawline through C | itation if not in conformance and not |
| Signature | ideard whether or not citation is in conformar | IOS ANTILIAN CT. AAA. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Considered include copy of this form with next communication to applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO This collection of information is required by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including the process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete on the opposition form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering upon the individual case. Any comments on the USPTO. Time will vary depending upon the individual case. Any comments on the gathering upon the individual case. Any comments on the USPTO. This applicant is the complete deposition to the USPTO. This applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

| | | Judion Ad | di 1995, 110 persona er | | Complete if Known | <u> </u> |
|------------|---------------------|------------|-------------------------|------------------------|-------------------|----------|
| Substitute | e for form 1449/PTO | | | Application Number | 10/810,165 | |
| INFO | RMATION | I DIS | CLOSURE | Filing Date | 03/26/2004 | • |
| | | | PPLICANT | First Named Inventor | David S. F. Young | |
| | | | | Art Unit | 1642 | |
| | (Use as many sh | eets as ne | cessary) | Examiner Name | | |
| Sheet | 5 | of | 6 | Attorney Docket Number | 2056.040 | |

| xaminer nitials* | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|--------------|---|----------------|
| LAB | | S. KAYASTHA et al, "Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival", Clin. Cancer Res., 5:1073-1076 (May, 1999) | |
| | | S. KENNEL et al, "CD44 expression on murine tissues", J. Cell Science, 104:373-382 (1993) | |
| | | M. KHOURSHEED et al, "Expression of CD44s in human colorectal cancer", Pathology Oncology Research, 8 (3):170-174 (2002) | |
| | | G. KOOPMAN et al, "Activated human lymphocytes and aggressive non-hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44", J. Exp. Med., 177:897-904 (April, 1993) | |
| | | M. KUPPNER et al, "Differential expression of the CD44 molecule in human brain tumours", Int. J. Cancer, 50:572-577 (1992) | |
| | | C. MACKAY et al, "Expression and modulaton of CD44 variant isoforms in humans", J. Cell Biol., 124:71-82 (January, 1994) | |
| | | D. NAOR et al, "CD44 in cancer", Critical Reviews in Clinical Laboratory Science, 39(6):527-579 (2002) | |
| | | H. PONTA et al, "CD44: from adhesion molecules to signaling regulators", Nature Reviews, Molecular Cell Biology, 4:33-45 (January, 2003) | |
| | | J. ROSS et al, "Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma", Mod. Pathol., 9(8):854-860 (1996) | |
| | | M. SAMI et al, "Regulated expression of exon v6 containing isoforms of CD44 in man: downregulation during malignant transformation of tumors of squamocellular origin", J. Cell Biol., 122(2):431-442 (July, 1993) | |

| Examiner Signature | Shim Famul | Date Considered | 4/19/06 |
|-----------------------|---|-----------------------------|---------------------------------------|
| | the state of the second citation is in conformance with Mil | DED 609 Draw line through C | itation if not in conformance and not |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

P 10/SB/086 (08-03)

Approved for use through 07/31/2006. OMB 0551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

The Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| Under | the Paperwork Redu | ction Act | of 1995, no persons are | a required to respond to a collection of | Complete if Known |
|--------------|---|-----------|-------------------------|--|-------------------|
| Substitute f | for form 1449/PTO | | | Application Number | 10/810,165 |
| INFO | DMATION | DIS | CLOSURE | Filing Date | 03/26/2004 |
| STAT | INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | First Named Inventor | David S. F. Young |
| 317. | | | | Art Unit | 1642 |
| 1 | (Use as many shee | ets as ne | eessary) | Examiner Name | |
| Sheet | 6 | of | 6 | Attorney Docket Number | 2056.040 |
| | | | | | |

| xaminer | Cite No.1 | NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T² |
|---|--------------|--|----|
| LAB | | A. SCHRIJVERS et al, "MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck", Cancer Res., 53:4383-4390 (September, 1993) | |
| | | S. SEITER et al, "Prevention of tumor metastasis formation by anti-variant CD44", J. Exp. Med., 177:443-455 (February, 1993) | |
| - | | Y. SHIMIZU et al, "Dual role of the CD44 molecule in T cell adhesion and activation", J. Immunol., 143:2457-2463 (October, 1989) | |
| | - | T. STROBEL et al, "In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation", Cancer Res., 57:1228-1232 (April, 1997) | |
| | | J. STROOMER et al, "Safety and biodistribution of 99m Technetium-labeled anti-CD44v6 monoclonal antiody BIWA 1 in head and neck cancer patients", Clin. Can. Res., 6:3046-3055 (August, 2000) | |
| | - | N. VAN HAL et al, "Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform", Int. J. Cancer, 68:520-527 (1996) | |
| | + | S. WALLACH-DAYAN et al, "CD44-dependent lymphoma cell dissemination: a cell surface CD44 variant, rather than standard CD44, supports in vitro lymphoma cell rolling on hyaluronic acid substrate and its in vivo accumulation in the peripheral lymph nodes", J. Cell Science, 114:3463-3477 (2001) | |
| | - | M. ZAHALKA et al, "Lymph node (but not spleen) invasion by murine lymphoma is both CD44- and hyaluronate-dependent", J. Immunol., 154:5345-5355 (1995) | |
| | | V. ZAWADZKI et al, "blockade of metastasis formation by CD44-receptor globulin", Int. J. Cancer, 75:919-924 (1998) | |
| | - | | |

| | | Date | LI I. a. s. s. |
|------------|---|--------------------------|---------------------------------------|
| Examiner | of Doint | Considered | 17/19/06 |
| Signature | Company whether or not citation is in conformance with MPEP | Constants | itation if not in conformance and not |
| Oigitature | the state of citation is in conformance with MPEP | 609. Draw line uniough o | alduon in not in our man |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation is attached.

2 Applicant is to place a check mark here if English language Translation is attached.

3 Applicant's unique citation designation is attached.

4 Applicant's unique citation designation is attached.

5 Applicant is to place a check mark here if English language Translation is attached.

5 Applicant is to place a check mark here if English language Translation is attached.

5 Applicant is to place a check mark here if English language Translation is attached.

6 Applicant's unique citation designation is attached.

7 Applicant's unique citation designation is attached.

8 Applicant is to place a check mark here if English language Translation is attached.

9 Applicant is unique citation designation is attached.

9 Applicant is to place a check mark here if English language Translation is attached.

9 Applicant is unique citation designation is attached.

9 Applicant is unique citation designation is attached.

9 Applicant is unique citation designation form to the USPTO.

1 Applicant's unique citation designation form to the USPTO.

1 Applicant is unique citation designation for retain a benefit by the public which is other in the USPTO.

1 A

Inder the Party Reduction
Substitute for form 1449/P10

PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

| Complete if Known | | | | |
|------------------------|-------------------|--|--|--|
| Application Number | 10/810,165 | | | |
| Filing Date | 03/26/2004 | | | |
| First Named Inventor | David S. F. Young | | | |
| Art Unit | 1642 | | | |
| Examiner Name | | | | |
| Attorney Docket Number | 2056.040 | | | |

| | 1 | 1 | of | | Altornoy Doublet Hamilton | |
|-----------------------|--|--------------|---------------------------------|--------------------------------|--|---|
| Sheet | | . | <u> </u> | | | |
| | | | | U. S. PATENT | DOCUMENTS | Pages, Columns, Lines, Where |
| Examiner Initials* | Cite No.1 | | ent Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Relevant Passages or Relevant Figures Appear |
| | | Number-K | ind Code ^{2 (# known)} | 04/04/2004 | D. Young et al | |
| LAB | | US- 2004/00 | 001789A1 | 01/01/2004 | D. Young et al | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | - | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | - | US- | | | | |
| | - | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | ┼ | US- | | | | |
| - | + | US- | | | | _ |
| | + | US- | | | | |
| | +- | US- | | | | |
| | + | US- | | | | |
| | + | US- | | | | |
| | +- | US- | | | | |

| Examiner Initials* | Cite No. | Foreign Patent Document | Publication Date MM-DD-YYYY | MENTS Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | Τ° |
|--------------------|-------------|---|-----------------------------|---|---|----|
| LAB | | Country Code ³ "Number ⁴ "Kind Code ³ (if known) WO2003/055515 | 07/10/2003 | Arius Research Inc | | |
| | | | | | | |

| 1. | | | |
|-----------|-------------|----------------------------|--|
| | | Date | 4/19/2/ |
| Examiner | 17. 3 , F/I | Considered | 1/11/06 |
| Signature | almos made | CANADA ON Develope through | b citation if not in conformance and n |

Signature Considered 1/1706

EXAMINER: Initial it deference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of considered. Include copy of this form with next communication to applicant, applicant's unique citation designation number (optional). See Kinds Codes of considered. Include copy of this form with next communication to applicant, applicant is two-letter code (WIPO Standard ST.3). For USFTO Patent Documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by Japanese patent documents are serial number of the patent document. Skind of document by Japanese patent documents are serial number of the patent document. Skind of document by Japanese patent documents are serial number of the patent document. Skind of documents are serial number of the patent document. Skind of documents

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the This collection of information is required by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, uspections form to the USPTO. Time will vary depending upon the individual case. Any comments including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

To: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
of collection of information values it contains a wall OMB. o.s. Patent and Trademark Office; o.s. DEPARTMENT OF COMMERCE no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| Unde | er the Paperwork Redu | uction Act | of 1995, no persons are | e required to respond to a collection of information unless it contains a collection of information unless it | | |
|------------|-----------------------|------------|-------------------------|---|-------------------|--|
| Substitute | e for form 1449/PTO | | | Application Number | 10/810,165 | |
| INEC | DMATION | DIS | CLOSURE | Filing Date | 03/26/2004 | |
| STA | TEMENT B | SY AF | PPLICANT | First Named Inventor | David S. F. Young | |
| | | | | Art Unit | 1642 | |
| | (Use as many she | ets as ne | cessary) | Examiner Name | | |
| Sheet | 2 | of | 2 | Attorney Docket Number | 2056.040 | |
| | | | | | | |

| | C:10 | NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the article (when appropriate), volume-issue | T ² |
|-----------------------|--------------|--|----------------|
| Examiner Initials* | Cite No.1 | the item (book, magazine, journal, serial, symposium, catalog, star) the item (book, magazine, journal, serial, symposium, catalog, star) the item (book, magazine, journal, serial, symposium, catalog, star) the item (book, magazine, journal, serial, symposium, catalog, star) the item (book, magazine, journal, serial, symposium, catalog, star) the item (book, magazine, journal, serial, symposium, catalog, star) the item (book, magazine, journal, serial, symposium, catalog, star) the item (book, magazine, journal, serial, symposium, catalog, star) the item (book, magazine, journal, serial, symposium, catalog, serial, symposium, catalog, star) the item (book, magazine, journal, serial, symposium, catalog, serial, symposium, catalog, serial, symposium, catalog, star) the item (book, magazine, journal, serial, symposium, catalog, symposium, catalo | 1- |
| LAB | | D. YOUNG et al, "ARH460-16-2: A therapeutic monoclonal antibody targeting CD44 in Her2/neu negative breast cancer", Journal of Clinical Oncology, 22:193s (July, 2004) Abstract 2622 | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | 1 | | |
| | | | |
| | +- | | |

| | | Date | 1111 - 101 |
|-----------|--|-----------------------|--|
| Examiner | (ار ج م | Considered | 1 7/19/06 |
| Signature | When Shadd | | citation if not in conformance and not |
| | whether or not citation is in conformance with MPE | 909. Diswille through | MISSION II LICK III COLLICE THE |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation is attached.

2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation if not in conformance and not considered.

2 Applicant is to place a check mark here if English language Translation is attached.

3 Applicant is to place a check mark here if English language Translation is attached.

4 Applicant's unique citation designation is attached.

5 Applicant is to place a check mark here if English language Translation is attached.

5 Applicant is to place a check mark here if English language Translation is attached.

6 Applicant is to place a check mark here if English language Translation is attached.

7 Applicant is to place a check mark here if English language Translation is attached.

8 Applicant is to place a check mark here if English language Translation is attached.

9 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation is attached.

1 Applicant is to place a check mark here if